Associate Professor University of Texas Southwestern Medical Center Dallas, Texas, United States
Disclosure(s):
Matthew Porembka, MD: No financial relationships to disclose
Patients with resectable gastroesophageal junction (GEJ) adenocarcinomas are often treated with neoadjuvant therapy. Treatment options include the FLOT chemotherapy regimen and the CROSS chemoradiation regimen. However, there are no guidelines on how to prioritize one over the other. How do we decide which regimen to use for patients with GEJ adenocarcinomas?
